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Abstract
We have previously shown that the defective ability of alveolar macrophages (AM) to phagocytose apoptotic cells
(‘efferocytosis’) in chronic obstructive pulmonary disease/emphysema (COPD) could be therapeutically improved using the
C-type lectin, mannose binding lectin (MBL), although the exact mechanisms underlying this effect are unknown. An S-type
lectin, galectin-3, is also known to regulate macrophage phenotype and function, via interaction with its receptor CD98. We
hypothesized that defective expression of galectin/CD98 would be associated with defective efferocytosis in COPD and that
mechanisms would include effects on cytoskeletal remodeling and macrophage phenotype and glutathione (GSH)
availability. Galectin-3 was measured by ELISA in BAL from controls, smokers and current/ex-smokers with COPD. CD98 was
measured on AM using flow cytometry. We assessed the effects of galectin-3 on efferocytosis, CD98, GSH, actin
polymerisation, rac activation, and the involvement of PI3K (using b-actin probing and wortmannin inhibition) in vitro using
human AM and/or MH-S macrophage cell line. Significant decreases in BAL galectin-3 and AM CD98 were observed in BAL
from both current- and ex-smoker COPD subjects vs controls. Galectin 3 increased efferocytosis via an increase in active GTP
bound Rac1. This was confirmed with b-actin probing and the role of PI3K was confirmed using wortmannin inhibition. The
increased efferocytosis was associated with increases in available glutathione and expression of CD98. We provide evidence
for a role of airway lectins in the failed efferocytosis in COPD, supporting their further investigation as potential
macrophage-targeted therapies.
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Background
Chronic Obstructive Pulmonary Disease/emphysema (COPD)
is a disease that is poorly managed with currently available
therapies. The World Health Organization estimates that 80
million people have moderate to severe COPD and this will be the
third leading cause of death world-wide by 2030 [1). There still
exist gaps in the understanding of the pathogenic mechanisms of
the disease; however, we have shown a significant defect in the
ability of pulmonary macrophages to phagocytose apoptotic
airway epithelial cells (defective efferocytosis) [2–4], which
contributes to an excess of apoptotic material present in the
airways of these patients [5]. This uncleared material can then
undergo secondary necrosis and perpetuate chronic inflammation
[5,6]. We have also demonstrated impaired phagocytosis of
bacteria in COPD; an important finding given the increased
bacterial colonization and increased susceptibility for infection/
exacerbation [7].
Lectins are soluble carbohydrate-binding proteins that include
C-type (lung surfactants and mannose binding lectin (MBL)), S-
type (galectins), L-type, heparin binding proteins and pentraxins.
They contain carbohydrate recognition domains (CRD) and are
traditionally recognised for their roles in recognition of pathogen-
associated molecular patterns (PAMPs) and facilitation of patho-
gen clearance [8–11]. More recently we and others have shown
that lectins also have the ability to facilitate phagocytosis of
apoptotic cells [12,13]. MBL, for example, has been shown to
recognize nucleic acids including fragmented DNA on apoptotic
cells, products of tissue damage (eg, heat shock proteins, cell
membrane material) [8]. We have shown that defective effer-
ocytosis in COPD (and other chronic inflammatory lung diseases,
including bronchiolitis obliterans syndrome following lung trans-
plantation) is associated with a decrease in airway levels of several
C-type lectins including MBL and surfactants [14,15], although
levels of S-type lectins have not been assessed in COPD. We
further showed that MBL administration to smoking mice
improved efferocytosis and reduced inflammation; however, the
precise mechanisms for this effect are unclear [16].
Both MBL and galectin-3 have been shown to have effects on
components of the actin reorganization pathway that occurs
during the phagocytic process. We showed that the pro-
efferocytosis effects of MBL were accompanied by an increase in
intracellular Rac1/2/3 [16]. Galectin-3 has also been shown to
activate phosphatidylinositol 3-kinase (PI3K), which has a well-
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recognized role in the reorganization of the actin skeleton and
activation of Rac, during myelin phagocytosis in microglia [17].
Lectins may also contribute to intracellular production of
glutathione (GSH), an antioxidant present in the lung that is
important for effective efferocytosis [18,19]. The availability of
extracellular GSH is essential to maintain intracellular GSH
homeostasis; when GSH availability is limited, cellular functions
including efferocytosis and respiratory burst are reduced [18].
GSH is produced following transport of its precursor amino acid,
cystine, into the cell via its transporter- xCT/CD98 [20]. Both
MBL and galectin-3 bind to CD98 [8,21], and the interaction of
galectin-3 and CD98 has been shown to induce an ‘M2’
alternatively activated macrophage phenotype (with an improved
efferocytosis ability) [18,21]. It is therefore possible that low levels
of galectin-3, or reduced expression of CD98, could compromise
the levels of GSH and subsequent efferocytosis ability of airway
macrophages, and play a role in the defective efferocytosis
observed in COPD.
We firstly measured galectin-3 and macrophage CD98 expres-
sion in the airways of well-categorized controls, smokers and
COPD groups. We then determined whether administration of
exogenous galectin-3 would improve efferocytosis in vitro, and
investigated potential mechanisms for this effect including in-
creased GSH availability, effects on macrophage phenotype, actin
polymerisation, Rac1 activation, and the involvement of PI3K.
Methods
Bronchoscopy and Preparation of Alveolar Macrophages
(AM)
Ethical approval was granted by the Royal Adelaide Hospital
Ethics Committee and written informed consent was obtained for
each patient or control recruited for the study. Flexible bronchos-
copy was performed and bronchoalveolar lavage samples (BAL)
obtained according to recommendations by the American
Thoracic Society as previously reported [2–4]. The diagnosis of
COPD was established using the GOLD criteria (FEV1/FVC
,70%) with clinical correlation [22].
Alveolar macrophages from BAL were prepared as previously
reported [2–4]. Briefly, macrophage cell counts in BAL were
adjusted to 46105/mL in RPMI 1640 media, supplemented with
10% foetal calf serum, 1% weight per volume L-Glutamine and
penicillin/streptomycin (Gibco BRL, Berlin, Germany) (culture
medium). One mL aliquots were then adhered to 24 well culture
plates for 2 h, then fluid removed and the purified macrophages
gently recovered using ice-cold culture medium and gentle
pipetting. We have previously shown that this process results in
no significant changes in apoptosis or macrophage function (data
not shown). Total and differential cell counts were obtained and
the macrophage cell counts adjusted to 46105/ml in culture
medium Macrophages were purified by adhesion to plastic as
previously reported [2–4].
Human Subjects
BAL galectin-3 was evaluated for (i) never-smoker controls
(n = 15) (ii) healthy smoker controls (n = 12) (iii) healthy ex-smoker
controls (n = 8) (iv) subjects with moderate severity COPD (30; 18
current smokers and 12 ex-smokers) (Table 1). All ex-smokers had
ceased smoking for at least 12 months.
Reagents and Antibodies
For assessment of CD98 expression, CD98-PE (BD Biosciences,
San Jose, CA) and CD14 and CD45 [phycoerythrin cyanide-5
(PC-5)] (Immunotech/Coulter) were employed. For assessment of
the efferocytosis function of human AM, CD33 [phycoerythrin
cyanide-5 (PC-5)] (Immunotech/Coulter, Marseille, France) and
mitotracker red (Molecular Probes, Oregon, USA) were employed.
For assessment of efferocytosis in a MH-S cell line, MHC II (I-A/
I-E) [fluorescein isothiocyanate [FITC)] (eBiosciences, San Diego,
California, USA) and mitotracker red were used. Recombinant
human galectin-3 was produced and purified as previously
described [23]. For the Rac1 pull-down assay, anti-Rac1 and
anti-Cdc42 were obtained from Millipore. For actin studies,
rhodamine phalloidin was obtained from Molecular Probes.
Leupeptin, aprotinin, NaF, Na3VO4 and 2-vinylpyridine were
obtained from Sigma Chemical Company Ltd (St Louis, Missouri,
USA). B-actin antibody was purchased from Cell Signaling
(Danvers, Massachusetts, USA).
ELISA Measurement of Galectin-3
Galectin-3 levels were determined in batches of frozen BAL
samples (after removal of cells) from subjects with COPD and
control subjects using commercial ELISA kits (R&D Systems
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(Minneapolis, MN)) following the procedure recommended by the
manufacturer. Galectin-3 concentration was expressed as nano-
grams of protein/mL. The mean minimum detectable dose was
0.016 ng/mL.
Flow Cytometric Analysis of CD98 on AM
Flow cytometry was utilized to assess expression of CD98 on
AM from a cohort of subjects as previously reported [3].
Efferocytosis Assay
Flow cytometry was utilized to assess the ability of AM to
phagocytose apoptotic bronchial epithelial cells as previously
reported [2–4].
Cell Lines
A murine alveolar macrophage cell line (MH-S; CRL-2019;
American Type Culture Collection, Manassas, VA) was main-
tained in RPMI-1640 medium supplemented with 10% FCS,
sodium pyruvate (1 mM), L-glutatmine, HEPES (10 mM), sodium
bicarbonate (1.5 g/L), b-mercaptoethanol (0.05 mM) and genta-
mycin. Normal mouse mammary gland epithelial cells (NMuMG)
were maintained in DMEM (Gibco) Invitrogen, Auckland, New
Zealand) supplemented with 10% FCS, 10 mg/mL insulin,
100 U/mL penicillin, and 50 mg/mL streptomycin. 16 HBE
bronchial epithelial cells for the efferocytosis assay were main-
tained as previously reported [2].
Effect of Galectin-3 on Efferocytosis in vitro
AM collected from 4 of the control subjects and 7 subjects with
COPD were incubated with galectin-3 (50 or 100 mg/mL) or
media control for 10 min at 37uC in serum free media before the
addition of apoptotic airway epithelial cells (ratio 4:1) and
assessment of efferocytosis as previously reported [2–4]. To
address if these effects were mediated by its carbohydrate-binding
domain we tested the effect of galectin-3 on efferocytosis in the
Figure 1. Decreased levels of galectin 3 in BAL in COPD. Galectin-3 analyzed by ELISA in stored samples of BAL from never-smoker controls
(n = 15), healthy smoker controls (n = 12), healthy ex-smoker controls (n = 8) and 30 subjects with moderate severity COPD (18 current-smokers and
12 ex-smokers).Box plots present median625th and 75th percentiles with the 10th and 90th percentiles shown by whiskers outside the box.
*p,0.05; **p,0.01 vs. never smoker controls.
doi:10.1371/journal.pone.0056147.g001
Figure 2. Decreased AM expression of CD98 in COPD.
Percentage of alveolar macrophages (AM) expressing CD98. CD98 was
measured by flow cytometry on AM from 8 never-smoker control
subjects and 11 subjects with COPD (6 current smokers and 5 ex-
smokers). Data presented as box plots as described in Figure 1.
*p,0.05; **p,0.01 vs. never smoker controls.
doi:10.1371/journal.pone.0056147.g002
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presence of lactose (5 mM), a disaccharide, competitive for
carbohydrate-binding by galectin-3.
Effect of Galectin-3 on Arginase-1 Activity
Activity of arginase-1, a marker of alternative macrophage
activation, was measured in supernatants from AM collected from
the 5 healthy controls that had been incubated with galectin-3 for
48 h, using a commercial QuantiChrom TM Arginase Assay Kit
(BioAssay Systems, Hayward, CA, USA) as previously described
[4].
Intracellular Glutathione-redox Assays
The glutathione-redox is the ratio of reduced glutathione (GSH)
to oxidized glutathione (GSSG). GSH and GSSG levels were
measured as we have previously described [24]. Briefly, MH-S
macrophages were treated varying concentrations of galectin-3 for
2 h and suspended in ice-cold extraction buffer (1% Triton X-100
and 0.6% sulfosalicyclic acid) and lysed by repeated freezing and
thawing. Lysates were centrifuged (10,0006g) for 5 min at 4uC
before measurement of GSH and GSSG. Oxidized Glutathione
(GSSG) was measured after derivatizing the reduced GSH with 2-
vinylpyridine (1 M). Oxidized GSH standards were used and the
GSSG-to-GSH ratio calculated.
Involvement of PI3K in Galectin-3 Induced Efferocytosis
MH-S macrophages were seeded in 24-well plates at 26105
cells/well and incubated overnight. Cells were pre-treated with the
PI3K inhibitor wortmannin (5–50 nM) for 30 min at 37uC, prior
to treatment with galectin-3. The efferocytosis assay was
performed using NMuMG mouse epithelial cells as phagocytic
targets as previously reported [16].
Effect of Galectin-3 on Rac Activation
Rac pull-down activity assays were performed according to the
manufacturer’s indications (Millipore). Briefly, 5.06106 MH-S
macrophages were plated overnight in reduced serum conditions
and were exposed to galectin-3 (50 mg/mL) for 10 min prior to the
addition of apoptotic NMuMG cells. Non-ingested cells were
removed. Cell extracts were prepared at 4uC from equal amounts
of cell protein, using prechilled Mg2 lysis buffer (125 mM HEPES,
750 mM NaCl, 5% Igepal CA-630, 50 mMMgCl2, 5 mM EDTA
and 10% glycerol; with the following inhibitors: 10 mg/mL
leupeptin, 10 mg/mL aprotinin, 1 mM sodium orthovanadate,
and 1 mM sodium fluoride). Extracts were cleared by centrifuga-
tion for 10 min at 4uC in the presence of glutathione agarose. Fifty
mL samples were withdrawn for analysis of total Rac1 and b-actin
Figure 3. Galectin-3 increases efferocytosis in vitro. AM from 4
control subjects and 7 subjects with COPD were incubated with or
without 100 mg/mL galectin-3 (Gal-3) for 10 min prior to efferocytosis
assay. To address if these effects were mediated by its carbohydrate-
binding domain we also tested the effect of galectin-3 on efferocytosis
in the presence of lactose (5 mM). (A) Data presented by box plots as
described in Figure 1. p,0.01 versus control with no galectin-3 added.
(B) Individual data points showing % efferocytosis pre- and post-
treatment with 100 mg/mL Gal-3.
doi:10.1371/journal.pone.0056147.g003
Figure 4. Galectin-3 increases AM arginase secretion. AM from 5
healthy controls were treated with galectin-3 (100 mg/mL) for 48 h.
Arginase was measured in culture supernatant by ELISA. p,0.05 versus
control with no galectin-3 added.
doi:10.1371/journal.pone.0056147.g004
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to ensure equal loading. The remainder of each extract was
incubated for 1 h at 4uC with 10 mL of p21-activated kinase-PBD
agarose (50% slurry), which selectively binds the active or GTP-
loaded forms of Rac and Cdc42. The beads were washed three
times with assay buffer and eluted with SDS-PAGE sample buffer.
The eluates were then subjected to immunoblot analysis using
Rac1-specific antibody.
Figure 5. Galectin-3 increases available glutathione. MH-S macrophages were treated with varying concentrations of galectin-3 for 1 h. Cells
were lysed and intracellular concentrations of GSH (A) reduced (available) GSH (B) oxidized GSH (GSSG) and (C) the ratio of GSH to GSSG were
measured following enzymatic recycling assay. Data represent mean 6 SEM of 4 separate triplicate experiments. *p,0.05 versus control.
doi:10.1371/journal.pone.0056147.g005
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Effect of Galectin-3 on Actin Polymerization
MH-S cells were seeded in 8-well chamber slides (BD
Biosciences, Bedford, MA, USA) overnight and treated with
galectin-3 for 10 min prior to the addition of UV-irradiated
apoptotic epithelial cells that been labeled with 200 nM
MitoTracker Green [2]. Non-ingested cells were removed and
cells were fixed with 4% paraformaldehyde. Cells were permea-
bilized with 0.1% Triton X-100. Cells were stained with
rhodamine-phalloidin for 20 min at room temperature in the
dark. Coverslips were mounted with Moval and images were
captured using a Bio-Rad Radiance 2100 confocal microscope (at
Detmold Imaging Core Facility, Hanson Institute) and Biorad
LaserSharp 2000 software for image viewing and processing. In
Figure 6. Galectin-3 improves efferocytosis by effects on PI3K. MH-S cells were treated with different concentrations of the PI3K inhibitor
(wortmannin) prior to the addition of galectin-3 and assessment of efferocytosis. Data represent mean 6 SEM of 3 separate triplicate experiments.
*p,0.05; **p,0.01, versus galectin-3 with no wortmannin added.
doi:10.1371/journal.pone.0056147.g006
Figure 7. Involvement of PI3K in galectin-3 induced Rac1 activation. Serum-starved MH-S cells were pre-treated with 50 nM wortmannin or
diluent for 30 min before the addition of galectin-3 (50 mg/mL) and apoptotic target cells. Active GTP-bound form of Rac1 protein was isolated by
pull-down assay and compared to total Rac1 expression was used as a loading control. Data represent 4 separate triplicate experiments. The lanes of
the blots (top) correspond with the legends given below the bar diagram. *p,0.05 versus galectin-3 with no wortmannin added.
doi:10.1371/journal.pone.0056147.g007
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some experiments, wortmannin was added to assess the effects of
inhibition of PI3K on actin polymerization.
Statistical Analysis
The Kruskall-Wallis and Mann Whitney U tests were applied to
analyze the data. Analyses were performed using GraphPad Prism
software; p,0.05 was considered significant.
Results
BAL Galectin-3 Levels and AM CD98 Expression are
Decreased in COPD
Galectin-3 levels were significantly decreased in the BAL of both
current and ex-smoker COPD and healthy smoker subjects,
compared to controls; but not in healthy ex-smokers (Figure 1).
There was a small but significant decrease in percentage of AM
expressing CD98 from both COPD groups vs. controls (Figure 2)
and in mean fluorescence intensity of staining (data not shown).
There was no significant correlation between galectin-3 or CD98
and age (not shown). There were no significant associations
between BAL yield and levels of galectin-3 (correlation 0.073), and
no significant differences in galectin-3 levels between the low
recovery group (less than 30% instilled) versus higher recovery
group (greater than 30%) BAL (p= 0.291).
Galectin-3 Increases Efferocytosis, in vitro
Addition of recombinant human galectin-3 to AM in vitro
resulted in a dose-dependent increase in efferocytosis (77%
increase with 100 mg/mL, p =0.0028) which was inhibited in
the presence of lactose (Figure 3), showing that the stimulatory
effects of galectin-3 were mediated by its carbohydrate-binding
domain.
Galectin-3 Increases AM Arginase-1 secretion
There was a significant increase in levels of the alternative
activation marker (‘M2’), arginase-1, following treatment of AM
with 100 mg/mL galectin-3 for 48 h (Figure 4).
Galectin-3 Improves Available GSH
Treatment of MH-S cells with galectin-3 increased GSH and
the GSH/GSSG ratio in a dose-dependent manner, reaching
statistical significance at 100 mg/mL (Figure 5).
Galectin-3 Improvement in Efferocytosis is Mediated by
PI3K
MH-S macrophages were pre-treated with wortmannin (5–
50 nM) for 30 min prior to addition of 100 mg/mL galectin-3 and
apoptotic targets. Wortmannin significantly decreased the effects
of galectin-3 on efferocytosis (Figure 6).
Figure 8. Co-localization of apoptotic cells in F-actin rich
phagocytic cups and phagosomes in galectin-3 treated macro-
phages.MH-S macrophages were pre-treated with 50 mg/ml galectin-3
for 10 min before the addition of MitoTracker Green (MTG) labelled
apoptotic epithelial cells. After the indicated time periods, un-ingested
apoptotic targets were removed and the cells were fixed, permeabi-
lized, and treated with rhodamine-phalloidin to stain actin. (A)
Distribution of ingested apoptotic epithelial cells and (B) F-actin inside
macrophages. (C) An overlay of these images demonstrates F-actin
surrounding the apoptotic targets.
doi:10.1371/journal.pone.0056147.g008
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Galectin-3 Improvement in Efferocytosis is Mediated by
PI3K and Rac1 Activation
We assessed Rac1 activation in MH-S cells pre-treated with or
without the PI3K inhibitor wortmannin, and then challenged with
apoptotic cells in the presence of galectin-3. The active GTP
bound form of Rac1 was detectable in cells incubated with
apoptotic targets and significantly increased in the presence of
galectin-3 (Figure 7). Pre-treatment of cells with wortmannin
completely abolished the formation of active GTP-bound form of
Rac1. Note that the total amount of Rac1 protein was similar in
the treatment groups; this was further confirmed with ß-actin
probing indicating that GDP-GTP exchange was inhibited by
wortmannin (Figure 7).
Figure 9. Role for PI3K in F-actin rich phagocytic cups and phagosomes in galectin-3 treated macrophages.MH-S cells were pre-treated
with wortmannin before challenge with labeled apoptotic cells in the presence or absence of galectin-3. The cells were then fixed and stained with
rhodamine-labeled phalloidin. The appearance of the actin-rich areas was noticeable after 30 min incubation. PI3K inhibition by wortmannin
attenuated phagocytosis and the formation of actin-rich phagocytic cups.
doi:10.1371/journal.pone.0056147.g009
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Actin Rearrangement Induced by Galectin-3 is Inhibited
by Wortmannin
MH-S cells were pre-treated with wortmannin before challenge
with labeled apoptotic cells in the presence or absence of galectin-
3. The cells were then fixed and stained with rhodamine-labeled
phalloidin. Co-incubation of MH-S cells with galectin-3 and
apoptotic cells induced the formation of actin-rich phagocytic cups
around the ingested apoptotic targets (Figure 8). The appearance
of the actin-rich areas was noticeable after 30 min incubation
(Figure 9). PI3K inhibition by wortmannin attenuated phagocy-
tosis and the formation of actin-rich phagocytic cups (Figure 9).
Discussion
Our data indicates a potential role for extracellular galectin-3 in
the failed efferocytosis that occurs in COPD, and shows that the
mechanisms include effects on cytoskeletal remodelling, macro-
phage phenotype and GSH availability. Both galectin-3 and its
receptor CD98 were decreased in the airways of both current and
ex-smoker COPD. Galectin-3 was also significantly reduced in
BAL from healthy smokers, indicating at least a partial potential
effect of cigarette smoke. However, consistent with our findings
with MBL, we also noted significant changes in ex-smoker COPD
subjects who had ceased smoking indicating that the defects
continue once COPD is established, despite cessation of smoking.
A significantly lower volume of BALF was recovered from both
current and ex-smokers with COPD, compared to healthy
controls, consistent with our previous studies. It should be noted
that low recovered BAL fluid tends to contain less alveolar lining
fluid, potentially resulting in relatively low concentrations of
soluble mediators and more neutrophils (that could express/
interact with CD98). We did not, however, note any differences in
the percentage of neutrophils in BALF from any group.
Previous studies from our group and others have highlighted the
importance of deficiencies in BAL levels of soluble lectins
including MBL in the pathogenesis of COPD [14]. Only one
study implicated a role for galectin-3; intracellular expression was
increased in the small airway epithelium and alveolar macro-
phages of severe COPD patients [25]. While this appears
contradictory to our results, the pleiotrophic functions of
galectin-3 are important in the interpretation of these results.
There is a significant amount of evidence which demonstrates that
biological effects of galectin-3 depend on its intracellular or
extracellular location. Extracellular galectin-3 has been shown to
induce apoptosis in activated T-cells [26], while intracellular
galectin-3 protects cells from apoptosis and promotes their
proliferation [27].
Interestingly, both MBL and galectin-3 bind to CD98 [8,21],
and the interaction of galectin-3 and CD98 has been shown to
induce an ‘M2’ alternatively activated macrophage phenotype
[21] (with improved ability to phagocytose apoptotic cells). The
reduced expression of galectin-3, MBL and CD98 are thus
consistent with our previous findings of a mixed but predomi-
nantly ‘M1’ phenotype in the airways in COPD, with reduced
efferocytic ability. We showed that the pro-efferocytosis effects of
galectin-3 are likely to involve its effects on macrophage
phenotype, as galectin-3 was able to steer AM to a more ‘M2’
phenotype, evident by an increase in arginase release.
Previous studies have demonstrated a role for lectins, including
galectin 3, in host defence against pathogens by promoting
opsonisation by complement and/or pathogen clearance by host
macrophages [28–30]. The uptake of beads in the presence of
galectin-3 could be prevented by the addition of lactose, via
mechanisms that include carbohydrate recognition [30]. We have
now shown that exogenous galectin-3 also improved efferocytosis
via similar mechanisms. While the dose of galectin-3 used in our
studies was quite high, previous studies have shown that levels of
extracellular galectin-3 can be as high as 50 mg/mL in BAL after
infection in murine models [31], and we did not find any evidence
of cell death as a result of galectin-3 treatment in our study.
In this study we were particularly interested in dissecting the
mechanisms for the effects of lectins on efferocytosis. Rac1 is
a small GTPase which regulates the reorganization of the actin
cytoskeleton by activating various effector molecules [32]. We
previously showed that the pro-efferocytosis effects of MBL were
accompanied by an increase in intracellular Rac1/2/3, suggesting
an effect on the actin reorganization that occurs during the
phagocytic process [16]. In the present study we showed that the
efferocytosis-enhancing effects of galectin-3 were accompanied by
reorganization of actin and an increase in active Rac. These
changes were significantly attenuated by the inhibition of PI3K,
not surprising given the pivotal role that PI3K plays in remodeling
of the actin cytoskeleton, enabling the formation of phagocytic
cups and, subsequently, the ability of the phagosome to internalize
the apoptotic cell target [21]. It should be noted that the
attenuation was only partial, implicating the potential involvement
of further factors in the galectin-3 effects. Interestingly, a recent
study investigating phagocytosis of degenerated myelin by
microglia also showed that galectin-3 improved phagocytosis by
upregulating and prolonging K-Ras-GTP dependent PI3K activity
and also by upregulating expression of complement 3 and
scavenger receptor AI/II [17]. Extending our studies to include
other inhibitors and assessing the effects of galectin-3 on arginase
activity using AM from COPD subjects would provide additional
interesting data.
We then showed that a second potential mechanism may be the
effect of lectins on intracellular production of glutathione (GSH).
We have showed decreased GSH availability in COPD airways [4]
and confirmed with our smoking murine model the role of GSH in
the failed efferocytosis in COPD [4]. We now demonstrate that
galectin-3 improves available intracellular macrophage GSH.
Galectin-3, as an endogenous ligand for CD98 [8,21], when
present at normal (high) concentrations could cross-link xCT/
CD98 and increase intracellular cystine and its conversion to
cysteine and thus increase synthesis of GSH [20,33]. The low
levels of galectin-3 and reduced expression of CD98 in COPD
subjects are thus likely to compromise the levels of GSH and
subsequent efferocytosis ability of airway macrophages, and play
a role in the defective efferocytosis. In summary, our data
implicate a role for galectin-3 in the macrophage dysfunction that
occurs in COPD. Further studies will be important for a better
understanding of the links between galectin-3, smoking and
COPD.
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